Conditions under which immobilized platelets activate as well as capture flowing neutrophils.
Immobilized activated platelets present P-selectin and efficiently capture flowing neutrophils. We investigated how the treatment of the platelets affected whether adherent neutrophils rolled continuously or became immobilized. Washed platelets were maintained in a 'resting' state by Ca++ chelation, prostacyclin and theophylline. When these platelets were adhered to glass that had been coated with aminopropyltriethoxysilane (APES) they retained discoidal morphology. Compared to a confluent surface of spread platelets prepared by allowing heparinized platelet-rich plasma to settle on APES-glass, 'resting' platelets captured far fewer flowing neutrophils, which rolled rapidly. However, if neutrophils were perfused along with thrombin (>/= 0.2 U/ml), then the resting platelets rapidly changed shape, neutrophil binding increased markedly, rolling velocity decreased, and 40-70% of the neutrophils were immobilized via beta2-integrins. Similar effects could be induced using ADP perfused with the neutrophils. Thrombin did not itself activate neutrophils, and stationary adhesion could also be induced if platelets were treated with thrombin before addition of neutrophils. After thrombin treatment of platelets, rolling adhesion was only fully re-established after a prolonged period of washout. Thus, platelets presented a stable surface-bound agent able to activate neutrophils. Blockade of platelet-activating factor receptor, leukotriene B4 receptor, or CXC-chemokine receptor 1 (CXCR1) on neutrophils did not inhibit conversion from rolling to stationary adhesion, but blockade of CXCR2 maintained a higher proportion of rolling adhesion. Thus, platelets attached to damaged vessels may capture flowing neutrophils, but the stability of neutrophil deposition will depend on the scale of the local generation of platelet agonists such as thrombin and ADP.
Stone
P C
PC
Department of Physiology, The Medical School, University of Birmingham, Birmingham.
Nash
G B
GB
D001792:Blood Platelets / Q000502:physiology*; D002448:Cell Adhesion; D004305:Dose-Response Relationship, Drug; D006801:Humans; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D009637:Masoprocol / Q000494:pharmacology; D018375:Neutrophil Activation; D009504:Neutrophils / Q000502:physiology*; D019007:P-Selectin / Q000494:pharmacology
D016859:Lipoxygenase Inhibitors; D019007:P-Selectin; D009637:Masoprocol